Recruitment status changed
Before: Recruiting. After: Active not recruiting.
Study sponsor: Corcept Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: Recruiting. After: Active not recruiting.
Before: Sep 2026. After: Oct 2026.
Before: Active not recruiting. After: Recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs.. After: Measure: Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. Measure: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs Measure: Incidence of treatment-emergent AEs and SAEs Measure: Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug.
Before: Actual. After: Estimated.
Before: 249 participants (actual). After: 279 participants (planned).
Before: Actual. After: Estimated.
Before: 22 Oct 2024. After: Sep 2026.